Specific protein degradation is remaining explored as an alternative approach in cancer, whereby the purely natural protein degradation technique is co-opted for therapeutic reasons. Lately produced novel molecules identified as proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. One particular ligand binds towards the ‘protein https://www.directivepublications.org/journal-of-clinical-breast-cancer/